Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

<p>Abstract</p> <p>Background</p> <p>The randomized phase 3 LYM3001 trial in relapsed follicular lymphoma (FL) demonstrated higher overall (ORR) and complete response (CR) rates and prolonged progression-free survival (PFS) with bortezomib-rituximab versus rituximab. We report findings in high-risk...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Zinzani Pier, Khuageva Nuriet K, Wang Huaqing, Garicochea Bernardo, Walewski Jan, Van Hoof Achiel, Soubeyran Pierre, Caballero Dolores, Buckstein Rena, Esseltine Dixie-Lee, Theocharous Panteli, Enny Christopher, Zhu Eugene, Elsayed Yusri A, Coiffier Bertrand
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	BMC 2012-10-01
סדרה:	Journal of Hematology & Oncology
נושאים:	Bortezomib Follicular High risk Lymphoma Rituximab
גישה מקוונת:	http://www.jhoonline.org/content/5/1/67
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!